Trial Profile
A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Sep 2021 Results assessing the impact of treatment with abiraterone or enzalutamide as well as HSD3B1 gene mutation on steroid hormones, quantified by mass spectrometry (MS) in patients with CRPCpresented at the 116th Annual Meeting of the American Urological Association
- 03 Jun 2021 Results assessing acquired genomic contributors to cross-resistance in metastatic castration-resistant prostate cancer, published in the Clinical Cancer Research.
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.